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collated and analyzed descriptively. Results: The implementation of LED-guided 
drug picking significantly reduced near misses for wrong drug [7.18 ± 3.17 vs 2.71 ± 
1.36, p< 0.001] and wrong strength [3.47 ± 2.48 vs 1.82 ± 1.13, p= 0.02]. There was no 
significant difference in the frequency of picking near misses for wrong quantity 
[17.8 ± 9.88 vs 14.0 ± 4.64, p= 0.162]. Overall, there was a significant reduction in the 
frequency of total picking near misses [28.4 ± 13.2 vs 18.1 ± 5.44, p= 0.007]. Pharmacy 
staff’s acceptance towards LED-guided picking was generally positive with majority 
preferring the LED over no LED-guided drug picking. ConClusions: Incorporation 
of LED into drug picking significantly decreased near misses of wrong drug and 
strength that potentially prevented costly medication errors. Pharmacy staff were 
generally receptive to LED-guided picking.
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EvidEncE REviEw GRouP (ERG) cRitiquE of SyStEmatic REviEwS (SR) 
SubmittEd to nicE aS PaRt of SinGlE tEcHnoloGy aPPRaiSalS (Sta) oR 
multiPlE tEcHnoloGy aPPRaiSalS (mta) in tHE laSt tHREE yEaRS
Srivastava K, Rajora P, Gupta S, Bisen R
BresMed Health Solutions, Panjim, India
objeCtives: The aim of this review was to assess the critiques highlighted by the 
ERG for SR submitted to NICE by manufacturers as part of STA or MTA. Methods: 
ERG reports available on the NICE website were systematically searched for the 
last three years (2013-2015). The ERG comments in the documents were care-
fully assessed along with the submission documents. Emphasis was placed on 
ERG comments regarding search strategy design, electronic databases used for 
article retrieval, inclusion/exclusion criteria in SR, and reporting of SR methodol-
ogy. Results: Fourteen ERG comment documents were identified by the search 
conducted in May 2015. Ten documents were identified in 2013, three in 2014, and 
one in 2015. Comments on search strategies, such as incorrect search terms, miss-
ing terms, and wrong explosion, were made on seven submissions. Major findings 
such as chances of omission of key studies, missing intervention synonyms, and 
improper presentation of search strategies were cited in two submissions. Two sub-
missions did not search the minimum number of electronic databases indicated 
by NICE. ERG comments around SR inclusion/exclusion criteria were ambiguity in 
the study selection criteria, omission of the intervention of interest, selection of 
inappropriate follow-up duration, introduction of additional exclusion criteria at a 
later stage, exclusion of studies based on sample size, a clinically irrelevant primary 
outcome, exclusion of non-English studies even in cases of data gaps, and exclusion 
of some geographical subgroups without rationale. The write-up of SR was inad-
equate in two submissions because of ambiguity around the number of reviewers 
at each stage, unclarity around second check of extracted data, poor reporting of 
methodology, and an incorrect study selection flowchart. ConClusions: The ERG 
findings demonstrate a gap in manufacturer’s search strategy design, rationale for 
inclusion/exclusion criteria, and writing-up of the SR methodology which has led 
to additional work while providing clarifications to NICE.
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Evolution & influEncE of Hta in EmERGinG maRkEtS
Yong C, Jiang Y, Sun D, Duttagupta S
CBPartners, New York, NY, USA
objeCtives: The objective of this study was to analyze the influence and develop-
ment of 13 HTA bodies in select Emerging Markets. Methods: This study examined 
13 HTA bodies in Latin America (Argentina, Brazil, Colombia, and Mexico), Asia (Korea, 
Taiwan, China, Singapore, Malaysia, and Thailand), Africa (South Africa), Middle East 
(Saudi Arabia), as well as Central and Eastern Europe (Turkey). The countries were 
selected based on the diversity associated with the HTA evaluation process, and 
were assessed for their review timeline, influence on the pricing and reimbursement 
process, and anticipated future developments as indicated from their websites and 
other publications. Results: Among the 13 selected HTA bodies, five countries (KOR, 
TWN, BRA, TUR, and ARG) have a defined review timeline; assessment outcomes 
will generally become available within a 1-year of submission. However, a standard 
timeline has yet to be defined for the rest of the countries. Four countries (KOR, TWN, 
BRA, and MEX) have formal HTA bodies, and assessments are mandatory in the pric-
ing and reimbursement process. In other six countries (SGP, ARG, COL, THA, SAU, 
and TUR), HTA assessments may be considered in the pricing and reimbursement 
evaluation. For CHN / MYS / ZAF, although an HTA body is under development, it does 
not currently have any impact on the reimbursement decision-making. For future 
HTA developments, the focus remains on scope expansion, capability building, and 
international collaboration. ConClusions: Emerging markets have developed or are 
in the process of developing HTAs for the evaluation of formulary inclusion and as a 
method of cost containment. The HTA bodies in the selected emerging markets have 
varying impact over the pricing and reimbursement process. The ones with greater 
influence tend to have a defined review timeline and an HTA body that is a formal 
authority with a mandatory and / or influential assessment.
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aSSESSmEnt of conSumER likEliHood to adoPt an ElEctRonic HEaltH 
REcoRd (EHR) mobilE aPPlication and tHE imPact of PERcEivEd RiSk of 
PRivacy lEakS
Claeys C, Tomaszewski K, Radley C, Wasserman D
KJT Group, Inc., Honeoye Falls, NY, USA
objeCtives: This study was designed to understand consumer likelihood to adopt 
a mobile application designed to allow individuals to view their personal health 
record on a mobile device as a function of risk tolerance of private medical data 
leaks, including variability by various demographics. Methods: A representative 
(U.S.) sample of 1,000 adults completed an online survey about their interest in an 
EHR mobile application. Interest in the application was elucidating using a 7-point 
Likert scale and a standard gamble (SG) exercise. The multivariate relationship 
between overall likelihood of mobile application use and SG utilities, education level, 
age, income level, and satisfaction with personal physician was assessed. Results: 
impact of the HTA system will be revealed by the number of drugs recommended 
that are subsequently placed on the reimbursement list, and with what restrictions.
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diREct EvidEncE vERSuS lack of diREct EvidEncE and tHE imPact on 
Hta accEPtancE
Griffiths EA, Sheppard FR, Pathak S, Hendrich J, Martin RL, Lalli A
PAREXEL, London, UK
objeCtives: Health technology assessment (HTA) agencies generally prefer the 
submission of direct evidence when appraising new interventions; however, an 
absence of head-to-head trial data is relatively common and indirect comparison 
is often required to determine relative effectiveness. To inform future submissions, 
acceptance rates across six HTA agencies were compared between submissions 
presenting direct evidence (active-comparator studies) and submissions lacking 
direct evidence. Methods: All single HTA appraisals from 2014 for NICE (England), 
SMC (Scotland), CADTH (Canada), PBAC (Australia), IQWIG (Germany), and HAS 
(France) were included in the analysis, including resubmissions. Multiple technology 
appraisals, vaccination programmes, requests for advice, and submissions where 
the clinical evidence base was not described were excluded. The recommenda-
tion, reasoning behind the recommendation, and type of evidence presented were 
extracted. Fisher’s exact test was used to test for statistical significance. Results: 
In 2014, NICE accepted 92% (11/12) of all submissions presenting direct evidence 
versus 88% (7/8) of submissions lacking direct evidence, SMC accepted 79% (26/33) 
versus 87% (13/15), CADTH accepted 90% (9/10) versus 53% (10/19), PBAC accepted 
50% (26/52) versus 82% (14/17), IQWIG accepted 48% (13/27) versus 13% (2/15), and 
HAS accepted 97% (42/43) versus 92% (35/38). A lack of direct evidence tended to 
be acceptable in cases where hard endpoints could be compared, and in disease 
areas with small patient numbers or a lack of therapeutic alternatives. Adjusted 
indirect comparisons were generally favoured over unadjusted comparisons, where 
presented. ConClusions: With the exception of IQWiG (p= 0.025), acceptance rates 
for submissions reporting direct evidence were not significantly different to rates 
for submissions lacking direct evidence for each agency, although acceptance rates 
varied across HTA agencies. Single-arm or placebo-controlled trials continue to 
be viewed as acceptable clinical evidence by most HTA agencies when such study 
designs are justifiable, and when relative efficacy can be demonstrated through 
robust indirect comparison.
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HEaltH tEcHnoloGy aSSESSmEnt aRcHEtyPE: imPlication on launcH 
PlanninG and EvidEncE SyntHESiS
Mazumder D1, Kapoor A1, Gwatkin N2, Medeiros C3
1Optum Global Solutions, Noida, India, 2Geni Biopharma, Hampshire, UK, 3Optum Life Sciences, 
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objeCtives: We aimed to quantitatively segment the health technology assessment 
(HTA) agencies into functional archetypes to sort countries with similar functional 
objectives and process into one group. Methods: Through literature search, we 
developed a Likert scale comprising 77 question from 18 best practice principles, and 
6 functional domains. Each question is marked on a scale of 0-5, with higher score 
(4 or 5) indicating best practice/ease of accession and low score (0 or 1) indicating 
lack of guidance/difficulty in accession. Our scale includes the key attributes of HTA 
process, i.e. general submission process, pharmacoeconomics, pricing, and evidence 
requirements under six functional domains: transparency, process, technical, equity, 
speed and implementation. Results: We evaluated HTA guidelines and process 
of 66 HTA agencies worldwide, followed by scoring and weighted analysis. Using 
univariate analysis on total weighted score, we segregated the dataset into five 
percentiles, with definition reflecting functional objectives: 0-25% (Price Managers), 
26-50% (Formulary Managers), 51-75% (Cost Advisors), 76-90% (Value Appraisers), 
and 91-100% (Value Implementers). Characteristically, Price Managers (eg. Singapore, 
India, Hong Kong) are free pricing markets, where setting drug price is the only hur-
dle in market access. Formulary Managers (eg. US, China) control drug price based 
on budget and regulatory approval. Cost Advisors (eg. Brazil, Mexico) are emerging 
HTA agencies that use HTA to advice cost. Value Appraisers (eg. South Korea, New 
Zealand) perform HTA on regular basis, but regional requirements overcome imple-
mentation of findings to drug price and reimbursement. Value implementers (eg. 
England, Canada, Germany) are the most mature markets, with pay for performance 
measures being the primary functional objective. ConClusions: Our analysis pro-
vides a new approach to quantitatively benchmark and group HTA agencies into 
archetypes based on functional objectives and local priorities. Analysis at domain 
and principle level helps mapping the similarity of requirements by each archetype, 
enabling evidence-based launch planning.
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EvaluatinG tHE SafEty imPact of liGHt EmittinG diodE (lEd) GuidEd 
dRuG PickinG in an outPatiEnt PHaRmacy
Wong JK1, Shek PY2, Tan MC2, Chen LL2, Wong JA2, Gunawan Y2, Ong YS2
1Temasek Polytechnic, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore
objeCtives: Medication errors may occur during the drug picking process whereby 
the wrong drug, strength or quantity is picked. In May 2012, LED were installed 
and tagged to drug bins at the outpatient pharmacy in Singapore General Hospital 
with the intent to prevent these costly errors. Upon scanning a Quick Response 
(QR) code on the drug label, the LED corresponding to the drug bin will light up, 
signaling the picker to the correct drug bin. This study seeks to evaluate the safety 
impact of LED-guided drug picking and pharmacy staff’s acceptance of this sys-
tem. Methods: The primary outcome of this study is the safety of the drug picking 
process measured in terms of the frequency of picking near misses. Near miss data 
before (January to April 2012) and after (May to August 2012) implementation of 
LED-guided drug picking were extracted electronically for statistical comparison. 
A survey was administered on pharmacy staff (n = 50) to find out their accept-
ance on drug picking with and without LED-guidance. Data from the survey were 
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with final appeal results were included in the study. The appeals were grouped under 
broader disease area categories and the appeal decision materials were reviewed. 
The grounds of appeals and outcomes of each appeal were extracted. Summary 
statistics were used to present the number of rejected or upheld appeals. Results: 
The most common area of NICE appeals is oncology followed by rheumatology and 
respiratory diseases. More than 50% of the total appeals were lodged in oncology in 
which 30% were breast cancer. The majority of the appeals identified were dismissed 
by the appeal panel on all grounds submitted, whilst approximately a third of the 
appeals were upheld on individual points. ConClusions: The majority of appeals 
submitted to NICE have been rejected by the appeal panel on all grounds. This study 
has only summarized outcomes from NICE appeals, further analysis is required to 
assess factors that influence whether appeals are upheld.
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bioSimilaRS: accESSinG tHE uk maRkEt
Das P
Boehringer Ingelheim UK, Bracknell, UK
objeCtives: The EMA has in place evolving guidelines on biosimilars since 2005. 
Biologics Price Competition and Innovation Act (BPCIA) passed by the US Congress 
in 2009 brought focus on biosimilars in the US. The impending expiration of patents 
for many top-selling biologics has also made biosimilars commercially exciting. This 
research evaluates the national and local market access challenges facing biosimi-
lars in the short to medium term. Methods: Formal current positions from HTA 
bodies like NICE, SMC, AWMSG, as well as positions at a national level from payers in 
the NHS in England, Scotland, and Wales, where available, are reviewed to inform the 
national market access situation. Local market access considerations like focus on 
budgets, pricing, discounts and stakeholder perceptions are evaluated by checking 
formulary uptake of two recently (2015) launch biosimilars for infliximab – Remsima 
and Inflectra. Results: NICE, SMC, and the NHS in Scotland recently have or are 
known to be working on formal positions on biosimilars. NICE (for STAs) and SMC 
have recently decided not to appraise biosimilars and there were no questions from 
the AWMSG for the biosimilars it accepted for use recently. However, expected (30%) 
and actual (10%) list-price reductions have not matched. Local discounts, budget 
considerations as well as payer, physician, and patient perception can play a crucial 
role in getting biosimilars on formularies. ConClusions: The number of biosimi-
lars accessing the UK market is rising. By all counts formal HTA assessments are 
not to be regularly expected in the UK, leaving such agencies to focus on innovative 
medicines at a national level. Decision on access to biosimilars in the UK hinges 
crucially on local market issues like price and perception.
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comPaRiSon bEtwEEn Hta REPoRtS in vEnEto and Emilia RomaGna: 
dRuGS aSSESSmEnt dEciSion cRitERia and PRioRitiES
Bruno GM1, Valentino MC1, Oselin M2, Colombo GL2, Di Matteo S1
1S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, 2University of Pavia, Milan, 
Italy
objeCtives: To review and compare HTA reports produced by two Italian 
Regions: Veneto and Emilia Romagna. To highlight analogies and differences 
between the elements evaluated in the reports and the outcomes of the assess-
ments made. Methods: A descriptive analysis of HTA reports produced by the 
Coordinamento Regionale Unico sul Farmaco (CRUF) of Veneto and Commissione 
Regionale del Farmaco (CRF) of Emilia Romagna. In order to obtain a direct compari-
son on the assessment methods of the two regions, only reports regarding the same 
active principles were considered. The analysed reports were published between 
2011 and 2014. Coherently with the principle of transparency professed by these HTA 
institutions, all the data included in the analysis were directly obtained from the 
agencies’ websites. Results: For all of the 5 drugs analysed in the reports, Veneto 
and Emilia Romagna considered same elements, such as safety, comparators, indica-
tion, and concluded the identical results about them. Both Regions provided always 
the same efficacy studies; in 2 cases Emilia Romagna evaluated more secondary 
endpoints, while in 1 it considered more studies than Veneto, nevertheless the two 
regions drew equal conclusions about efficacy. Different approaches were taken 
when conducting economic evaluations: both Regions considered drugs’ costs but 
Emilia Romagna, on the contrary of Veneto, never developed neither a budget impact 
analysis nor a target population study. Finally, in 3 out of 5 cases Commissions 
drew different conclusions about the selection of patients to which give the drug 
to or whether including or not the drug in the Prontuario Terapeutico Regionale 
(PTR). ConClusions: Divergences in final decisions highlight different priorities 
of each HTA region regarding the criteria used to make evaluations. Because of the 
goal of transparency both Regions have, the lack of evidence of mechanisms they 
adopt in taking assessments should be filled.
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comPaRiSon of Economic Evaluation bEtwEEn tHREE majoR Hta 
aGEnciES. iS tHERE a fREncH toucH?
Levy P1, de Paz B2, Guigand G1, Porte F1, Carion PL1, Minacori R1, Popot C1, Bendebba L1, 
Kossi Dédé S1, Peirone V2, Renard C1, Vorimore A1
1Université Paris-Dauphine, Paris, France, 2PRIORITIS Market Access, Paris, France
objeCtives: The newly established French Economic Evaluation and Public Health 
Commission (CEESP) provides recommendations and opinions to decision mak-
ers about economic evaluations (EEs) for innovative and expensive treatments. 
In this context, our aim was to compare the differences between EEs conducted 
in three major health authorities in Europe: SMC, NICE and CEESP. Methods: 
Using the Prismaccess database, we identified all technology appraisals (TAs), 
excluding vaccines, published by CEESP prior to June 2015. For these products, 
we sought corresponding guidance published by English and Scottish agencies 
(NICE, SMC) and compared methodology and results of the EEs. Data collected 
for each TA included: study population, comparator, type of analysis, model, time 
horizon, perspective, clinical and utility data, costs and results. Results: We 
Prior to any indication of a potential privacy risk, 31% of consumers indicate they 
would be very likely to download an EHR mobile application (rated 6 or 7 on 7-point 
Likert scale; 4.0 mean). This likelihood decreased with age. After introducing variable 
levels of privacy risk, and within the multivariate framework, age and educational 
level revealed inverse statistical associations with risk tolerance (greater age and 
educational achievement were less likely to download the hypothetical app). In 
contrast, higher income levels and higher levels of patient satisfaction with their 
physicians were associated with greater likelihood to download. These results were 
statistically significant at α = 0.05. ConClusions: One in three consumers reports 
they would be very likely to download an EHR mobile application. Younger demo-
graphics are more likely to download the app and are more accepting of risk of those 
data being leaked to a 3rd party. While the likelihood to download the app increases 
with income level, higher levels of education may actually reduce the likelihood 
of downloading. Physician satisfaction is also a driver of increased likelihood to 
download the application.
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PREvalEncE and incidEncE EStimationS in GERman amnoG 
aPPlicationS – tHE RolE of REal-woRld EvidEncE (RwE)
Altevers J, Borchert K, Mittendorf T, Braun S
Xcenda GmbH, Hannover, Germany
objeCtives: 90% of the German population is insured in the statutory health 
insurance which covers nearly all healthcare services with only little co-payments. 
German health insurance claims data therefore constitute an important basis for 
real world evidence (RWE) on morbidity and healthcare costs. Aim of this study was 
to investigate to which extent RWE was used for estimation of prevalence and inci-
dence in German AMNOG assessments since introduction 4 years ago and its impact 
on price discounts. Methods: German AMNOG dossiers with published benefit 
assessments until March 2015 were evaluated. They were screened for use of RWE 
in assessing prevalence and incidence and also target populations. After descrip-
tion and discussion of methods and data sources used, statistics were applied to 
explore a potential influence of use and quality of RWE data on magnitude of price 
discounts. Results: 134 AMNOG dossiers were included of which 50% utilized 
RWE to assess prevalence, incidence, and target populations. German claims data 
were employed in 16 dossiers (24%), registry data in 7 dossiers (10%), and other data 
sources like Delphi panels in 49 dossiers (73%). Claims data were mostly applied 
for prevalence estimations of both the underlying disease and target populations. 
Compared to numbers stated by the Federal Joint Committee, target populations 
were accepted as reported in 56% and underrated numbers in 44% of those dossiers 
specifically using claims data. Price negotiations were completed for 80 AMNOG 
assessments. A t-test evaluating the association between use of RWE and negotiated 
price discounts indicated that price discounts were lower in assessments that did 
incorporate RWE data (p= 0.049). ConClusions: German claims data constitute 
a valuable and valid data source for assessing epidemiologic evidence in German 
AMNOG assessments and can be a valuable tool for subsequent price negotiations.
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tHE cHallEnGES of caRRyinG out an indiREct comPaRiSon witH 
SinGlE-aRm StudiES
Langham S, Pooley N, Madrigal AM
PHMR Ltd, London, UK
objeCtives: To assess guidance for using single-arm studies in indirect compari-
sons (ICs) to support health technology assessment submissions. ICs enable com-
parison of different treatments using data from separate studies. The published 
methodology for conducting ICs outline the requirement for multiple arm studies 
to form connections between direct and indirect evidence. This is not possible when 
trials have single arms, a particular issue for treatments for new indications or 
for rare diseases. Methods: Guidelines were searched for advice on the use of 
single-arm trial data in ICs: National Institute of Health and Care Excellence [NICE], 
Cochrane; Centre for Reviews and Dissemination; and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses. In addition the NICE website was searched 
for new drug submissions including single-arm studies in ICs. Results: There is 
minimal current guidance for dealing with single-arm studies in ICs. NICE recom-
mends that such analyses should be treated as observational and appropriate steps 
taken to adjust for possible bias. There are very few submissions where single-arm 
trial evidence has been used in an IC. Those that attempted to compare outcomes 
from single-arm studies were mostly in oncology and in many cases the reviewing 
committee had requested this additional information. Cost-effectiveness calcula-
tions using these data were acknowledged as being highly unreliable, even after 
attempts had been made to adjust for possible between-study bias. ConClusions: 
A number of methods could be used to compare results across multiple single-arm 
studies. A Bayesian hierarchical model that includes random effects allowing for 
heterogeneity between studies is a good choice. However, there is a need for clear 
guidance from organisations such as NICE and Cochrane, who provide recommen-
dations on carrying out systematic reviews and indirect comparisons, on this and 
other approaches to synthesising information from single-arm studies.
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nicE dEciSion makinG: to aPPEal oR not to aPPEal?
Vlachaki I, Murphy D, Hirst A
WG Access Ltd, London, UK
objeCtives: In order for NICE to issue final guidance regarding a new or existing 
medicine to the NHS, the appeal period for the technology appraisal has to have 
passed and if an appeal is submitted, it has to be resolved. The Appeal Panel con-
siders appeals which meet one or more of the grounds of appeal defined by NICE. 
The objective of this study was to identify the past appeal decisions and report 
the respective results. Methods: A review of past NICE appeals decisions was 
conducted via a comprehensive search of the NICE website. Published technology 
appraisals in which appeals were lodged were identified. Only completed appraisals 
